SYNGEN INC.

Profile

Company Names

SYNGEN INC.

Addresses

100 HOWE AVENUE, SUITE 185N, SACRAMENTO, CA 95825

2125 19TH STREET, SUITE 120, SACRAMENTO, CA 95818

2125 19TH STREET, SACRAMENTO, CA 95818

1919 21ST STREET, SUITE 203, SACRAMENTO, CA 95811

Phone Numbers

916.706.0923

 

Entity Type:

CORPORATION

Industry:

BIOTECHNOLOGY

Year Incorporated:

2012

State Incorporated:

DELAWARE

Total Amount Raised:

$15,213,422.00

Number of Funding Rounds:

14
Investment Rounds
Round #
Round Open Date
Amount Raised
Total Round Size
Amount Remaining to be Raised
Securities
14
2017-06-14 
$400,000.00 
$400,000.00 
$0.00 
Equity, Debt 
13
2017-04-18 
$500,000.00 
$500,000.00 
$0.00 
Equity, Debt 
12
2017-03-21 
$500,000.00 
$500,000.00 
$0.00 
Equity, Debt 
11
2017-02-21 
$500,000.00 
$500,000.00 
$0.00 
Equity, Debt 
10
2017-01-12 
$500,000.00 
$500,000.00 
$0.00 
Equity, Debt 
9
2016-11-14 
$1,000,000.00 
$1,000,000.00 
$0.00 
Equity, Debt 
8
2016-07-13 
$1,000,000.00 
$2,000,000.00 
$1,000,000.00 
Equity, Debt 
7
2016-04-26 
$1,563,422.00 
$1,563,422.00 
$0.00 
Equity, Debt 
6
2016-01-08 
$2,000,000.00 
$2,000,000.00 
$0.00 
Debt 
5
2015-03-25 
$2,250,000.00 
$3,000,000.00 
$750,000.00 
Debt 
4
2014-09-12 
$2,000,000.00 
$4,000,000.00 
$2,000,000.00 
Debt 
3
2013-12-27 
$0.00 
INDEFINITE 
INDEFINITE 
 
2
2013-07-02 
$1,000,000.00 
$3,000,000.00 
$2,000,000.00 
 
1
2012-04-17 
$2,000,000.00 
$5,000,000.00 
$3,000,000.00 
Equity 
People
First Name
Middle Name
Last Name
Titles
Related Companies
GEORGE 
 
BARRY 
EXECUTIVE OFFICER, DIRECTOR, PROMOTER
SYNGEN INC.
PHILIP 
H. 
COELHO 
EXECUTIVE OFFICER, DIRECTOR, PROMOTER
SYNGEN INC.
WILLIAM 
 
GERBER 
EXECUTIVE OFFICER, DIRECTOR
VIVALDI BIOSCIENCES INC   |  CONATUS PHARMACEUTICALS INC   |  ITC NEXUS HOLDING COMPANY, INC.   |  NABSYS INC   |  SYNGEN INC.
CARL 
 
GOLDFISCHER 
DIRECTOR
BRAINCELLS INC   |  ENTEROMEDICS INC   |  METABOLEX, INC.   |  PTC THERAPEUTICS, INC.   |  PHARMAKEA, INC.   |  SYNGEN INC.   |  SIDECAR THERAPEUTICS, INC.   |  IMARA INC.   |  GALECTO, INC.
WOODROW 
A. 
MYERS, JR. 
DIRECTOR
SYNGEN INC.
CHUCK 
 
NOVAK 
EXECUTIVE OFFICER
SYNGEN INC.
VIC 
 
SCHMITT 
DIRECTOR
VIVALDI BIOSCIENCES INC   |  SYNGEN INC.   |  XCEDE TECHNOLOGIES, INC.
Filings
Filing Date
Filing Type
Source URL
Industry Classifier
Detailed Industry
Revenue Range
Securities
First Sale Date
2017-06-26
D
Link
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
Equity, Debt 
2017-06-14 
2017-04-21
D
Link
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
Equity, Debt 
2017-04-18 
2017-03-24
D
Link
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
Equity, Debt 
2017-03-21 
2017-02-27
D
Link
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
Equity, Debt 
2017-02-21 
2017-01-19
D
Link
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
Equity, Debt 
2017-01-12 
2016-11-28
D
Link
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
Equity, Debt 
2016-11-14 
2016-07-26
D
Link
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
Equity, Debt 
2016-07-13 
2016-05-10
D
Link
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
Equity, Debt 
2016-04-26 
2016-02-10
D
Link
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
Debt 
2016-01-08 
2015-06-08
D
Link
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
Debt 
2015-03-25 
2014-09-22
D
Link
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
Debt 
2014-09-12 
2014-01-07
D
Link
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
 
2013-12-27 
2013-07-10
D
Link
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
 
2013-07-02 
2013-07-10
D/A
Link
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
Equity 
2012-04-17 
2012-04-24
D
Link
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
Equity 
2012-04-17 
Brokers
Broker Dealer
Broker CRD#
Recipient Name
Recipient CRD#